Compare CYN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYN | BLRX |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | Israel |
| Employees | 62 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 11.7M |
| IPO Year | 2021 | 2010 |
| Metric | CYN | BLRX |
|---|---|---|
| Price | $0.39 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 191.9K | 13.3K |
| Earning Date | 11-17-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $424.72 | $37.33 |
| Revenue Next Year | $596.26 | $37.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $1.95 |
| 52 Week High | $5.09 | $3.95 |
| Indicator | CYN | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 22.14 | 38.56 |
| Support Level | N/A | $1.95 |
| Resistance Level | $1.76 | $2.56 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 1.25 | 28.57 |
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.